Impact of COVID-19 lockdown on exercise capacity in PAH patients

Claudia Baratto1,2, Céline Dewachter2, Sergio Caravita1,3

  • 1Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano IRCCS Ospedale San Luca Milano Italy.

Insights

The COVID-19 lockdown reduced physical activity, negatively impacting exercise capacity in pulmonary arterial hypertension (PAH) patients. Six-minute walking tests showed a significant decrease in performance after the lockdown period.

Area of Science:

  • Cardiology
  • Pulmonology
  • Public Health

Background:

  • The COVID-19 pandemic led to global lockdowns and reduced physical activity.
  • Pulmonary arterial hypertension (PAH) patients may experience decreased exercise capacity due to reduced activity, especially if frail or with chronic conditions.

Purpose of the Study:

  • To assess the impact of the COVID-19 lockdown on the functional status of clinically stable PAH patients.
  • To compare exercise performance in PAH patients before and after the lockdown period using the 6-minute walking test (6MWT).

Main Methods:

  • An observational analysis included 63 clinically stable PAH patients.
  • Patients had performed at least four 6-minute walking tests (6MWT) between 2019 and 2020.
  • Exercise performance was compared before and after the COVID-19 lockdown in Belgium (March-June 2020).

Main Results:

  • A mean reduction of 14 meters in 6MWT distance was observed after the lockdown (p=0.004).
  • The average 6MWT distance decreased from 447m in March 2020 to 434m in June 2020, a significant loss of 13m (p=0.024).
  • Reduced performance occurred despite clinical stability and no signs of disease progression.

Conclusions:

  • COVID-19 lockdown-induced reduction in physical activity negatively affected exercise performance in PAH patients.
  • The impact on 6MWT performance should be considered when evaluating PAH patients during or after the pandemic.
  • Maintaining physical activity is crucial for preserving functional status in PAH patients.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
315
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
248
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
241
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
30
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.1K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
28